FibroGen Reports Second Quarter 2018 Financial Results
07 août 2018 16h02 HE
|
FibroGen, Inc
Roxadustat U.S. Phase 3 Topline Clinical Data Readout on Track for Fourth Quarter of 2018 Feedback from FDA on Pamrevlumab Pivotal Programs in IPF and in Locally Advanced Unresectable Pancreatic...
FibroGen to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018
01 août 2018 17h21 HE
|
FibroGen, Inc
SAN FRANCISCO, Aug. 01, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a biopharmaceutical company, today announced that it will report second quarter 2018 financial results on Tuesday,...
FibroGen Presents Latest Data From PRAISE Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at American Thoracic Society 2018
21 mai 2018 16h00 HE
|
FibroGen, Inc
SAN DIEGO, May 21, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a biopharmaceutical company, today announced that updated results from the company’s randomized, double-blind,...
FibroGen Reports First Quarter 2018 Financial Results
09 mai 2018 16h02 HE
|
FibroGen, Inc
Pamrevlumab Data to be Presented at ATS 2018 and ASCO 2018 Roxadustat U.S. Phase 3 Clinical Studies on Track to Readout in Fourth Quarter 2018Conference Call Today at 5:00 p.m. Eastern Time/2:00...
UPDATE - FibroGen Granted Fast Track Designation by U.S. FDA for Pamrevlumab Treatment of Patients with Locally Advanced Unresectable Pancreatic Cancer
01 mars 2018 13h45 HE
|
FibroGen, Inc
SAN FRANCISCO, March 01, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has...
Fibrogen Granted Fast Track Designation by U.S. FDA for Pamrevlumab Treatment of Patients with Locally Advanced Unresectable Pancreatic Cancer
01 mars 2018 07h00 HE
|
FibroGen, Inc
SAN FRANCISCO, March 01, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has...
FibroGen Reports Fourth Quarter and Full Year 2017 Financial Results
27 févr. 2018 16h11 HE
|
FibroGen, Inc
Roxadustat U.S. Phase 3 Program in CKD Anemia Enrollment Completion and Data Readout in 2018 Pamrevlumab Phase 2 IPF Study Achieves Statistically Significant Attenuation of Lung Fibrosis as Measured...
FibroGen Reports Third Quarter 2017 Financial Results
08 nov. 2017 16h02 HE
|
FibroGen, Inc
Roxadustat NDA Filing Accepted for CFDA Review; Positive Pamrevlumab Phase 2 IPF Results ReportedConference Call and Webcast to be Held Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time ...
FibroGen Granted Orphan Drug Designation for Pamrevlumab in the Treatment of Pancreatic Cancer
21 juin 2017 22h09 HE
|
FibroGen, Inc.
SAN FRANCISCO, June 21, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted...
About FibroGen, Inc.FibroGen to Present at the Goldman Sachs 38th Annual Global Healthcare Conference
13 juin 2017 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, June 13, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that Chief Executive Officer Thomas B. Neff will participate...